Criterium

Criterium, Inc. is a company based in Saratoga Springs, United States (Wikidata Q140045287, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. It leads four trials recorded in OnCo, none of a compound of its own: NCT06992258 (phase 2, fruquintinib with TAS-102 against fruquintinib alone in refractory metastatic colorectal cancer), NCT05230810 (phase 1/2, alpelisib with tucatinib in PIK3CA-mutant HER2-positive metastatic breast cancer), NCT04567420 (DARE, phase 2, circulating tumour DNA-guided second-line adjuvant palbociclib and fulvestrant in high-risk ER-positive HER2-negative breast cancer) and NCT05458674 (phase 2, tucatinib with trastuzumab and eribulin in pretreated HER2-positive metastatic breast cancer). The cro-services type reflects that pattern; Criterium's own description of its business was not consulted.